ByTrending Posts
Can AstraZeneca’s 2025 Execution Propel It to Leadership…
AstraZeneca concluded 2025 as a company demonstrating resilient performance, focused execution, and continued innovation across its pharmaceuticals and…
How Did Sanofi’s 2025 Deals Shape Its Strategy…
In 2025, Sanofi pursued a series of strategic collaborations, acquisitions, and licensing agreements aimed at strengthening its core…
What Lessons from Sanofi’s 2025 Execution Signal Its…
Sanofi concluded 2025 with a combination of solid portfolio performance, strategic execution, and continued innovation across its pharmaceuticals,…
How Did Roche’s 2025 Deals Shape Its Strategy…
In 2025, Roche executed a series of focused deals and collaborations designed to strengthen its scientific platforms, expand…
How Did Roche Navigate 2025 and What Lies…
Roche concluded 2025 as a company demonstrating resilient performance, strategic focus, and continued innovation across its pharmaceuticals and…
How Did Johnson & Johnson’s 2025 Deals Shape…
New Brunswick, NJ — In 2025, Johnson & Johnson executed a series of strategic collaborations, acquisitions, and partnerships…
How Did Johnson & Johnson Navigate 2025 and…
Johnson & Johnson concluded 2025 with a combination of resilient portfolio performance, strategic execution, and ongoing innovation across…
How Did Novartis’ 2025 Deals Shape Its Strategic…
Novartis’ deal activity in 2025 reflected a deliberate and strategic effort to strengthen its scientific platforms, broaden its…
How Did Novartis Navigate 2025 and What’s Ahead…
In 2025, Novartis demonstrated resilience and strategic focus, balancing strong performance in its core franchises with investments in…
Trending Posts
Latest Stories
AI Is Reshaping Pharma’s Economics—But Discovery Isn’t the Immediate Win
Executive Summary Artificial intelligence has moved from experimental promise to operational backbone across global biopharma.…
Can Takeda’s $1.7 Billion Iambic Deal Redefine AI-Driven Small-Molecule Drug Discovery?
Executive Summary In a landmark AI-biopharma transaction, Takeda Pharmaceutical Co Ltd has entered a multi-year…
Pfizer Repositions for Sustainable Growth in 2025 as Core Therapeutic Franchises Reassert Leadership
Pfizer Inc. reported full-year 2025 revenues of $62.6 billion, marking a pivotal year in the…
Eli Lilly Delivers Transformational Growth in 2025, Anchored by Metabolic Leadership and Innovation Execution
Indianapolis, IN – February 2026 – Eli Lilly and Company reported exceptional full-year financial and…
Gallery
